Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097575 | 0.89 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL6670010 | 0.86 | PIM3 (0.35) | KCNH2POLBALDH1A1OPRM1 | |
| SCHEMBL6671530 | 0.85 | KCNH2 (0.32) | KCNH2POLBKDM4EPRKD3ALDH1A1 | |
| SCHEMBL6672934 | 0.85 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL6668532 | 0.85 | ALDH1A1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL6671162 | 0.85 | KCNH2 (0.33) | KCNH2POLBKDM4EPRKD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7097502 | 0.84 | KCNH2 (0.47) | KCNH2 | |
| Hydrochloric Acid SCHEMBL7099514 | 0.84 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL6672228 | 0.84 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL6668975 | 0.84 | KCNH2 (0.38) | KCNH2POLBKDM4EPRKD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | KCNH2 143/4885POLB 3318/4885KDM4E 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.